Potential risks in fecal microbiota transplantation

Sok-Ja Janket; Leland K. Ackerson; Eleftherios P. Diamandis

doi:10.1515/cclm-2019-1076

Published by De Gruyter December 9, 2019

Potential risks in fecal microbiota transplantation

Sok-Ja Janket , Leland K. Ackerson and Eleftherios P. Diamandis

From the journal Clinical Chemistry and Laboratory Medicine (CCLM)

https://doi.org/10.1515/cclm-2019-1076

Showing a limited preview of this publication:

Keywords: fecal microbiota; live bacteria; microbiota transplatation; tumor growth

Corresponding author: Eleftherios P. Diamandis, MD, PhD, FRCP(C), FRSC, Head of Clinical Biochemistry, Mount Sinai Hospital and University Health Network, 60 Murray St. Box 32, Floor 6, Rm L6-201, Toronto, ON M5T 3L9, Canada; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; and Department of Clinical Biochemistry, University Health Network, Toronto, Ontario, Canada, Phone: +(416) 586-8443

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Janket SJ, Ackerson LK, Diamandis EP. Gut microbiotas and immune checkpoint inhibitor therapy response: a causal or coincidental relationship? Clin Chem Lab Med 2019;58:18–24.10.1515/cclm-2019-0605Search in Google Scholar PubMed

2. Kao D, Roach B, Silva M, Beck P, Rioux K, Kaplan GG, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent clostridium difficile infection: a randomized clinical trial. J Am Med Assoc 2017;318:1985–93.10.1001/jama.2017.17077Search in Google Scholar PubMed PubMed Central

3. Brandt LJ, Aroniadis OC, Mellow M, Kanatzar A, Kelly C, Park T, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012;107:1079–87.10.1038/ajg.2012.60Search in Google Scholar PubMed

4. Nieuwdorp M, Vrieze A, de Vos WM. Reply to Konstantinov and Peppelenbosch. Gastroenterology 2013;144:e20–1.23499287.10.1053/j.gastro.2013.02.036Search in Google Scholar PubMed

5. Mullish BH, Quraishi MN, Segal JP, McCune VL, Baxter M, Marsden GL, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridium difficile infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. J Hosp Infect 2018;100 Suppl 1:S1–31.10.1016/j.jhin.2018.07.037Search in Google Scholar PubMed

6. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014;505:559–63.10.1038/nature12820Search in Google Scholar PubMed PubMed Central

Received: 2019-10-17

Accepted: 2019-11-13

Published Online: 2019-12-09

Published in Print: 2020-03-26

Potential risks in fecal microbiota transplantation

References

Journal and Issue

Articles in the same Issue